MindRank Ltd, a China-based artificial intelligence (AI)-driven drug development company, has entered into a strategic partnership with domestic pharmaceutical firm Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267). The collaboration will combine MindRank’s AI platform technology with Hisun Pharmaceutical’s research and development (R&D) capabilities and manufacturing resources to advance the field of AI-assisted small-molecule drug research and development. The financial terms of the agreement were not disclosed.
Hisun Pharmaceutical, known for its advanced, multi-dimensional R&D platform, has established R&D centers in key locations including Taizhou, Shanghai, Hangzhou, and the United States, reinforcing its commitment to innovation in pharmaceutical research.- Flcube.com
